134 related articles for article (PubMed ID: 7696102)
1. Influence of steroid medication on bone mineral density in children with nephrotic syndrome.
Lettgen B; Jeken C; Reiners C
Pediatr Nephrol; 1994 Dec; 8(6):667-70. PubMed ID: 7696102
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral content and collagen metabolites in children receiving steroid treatment for nephrotic syndrome.
Esbjörner E; Arvidsson B; Jones IL; Palmér M
Acta Paediatr; 2001 Oct; 90(10):1127-30. PubMed ID: 11697422
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density in pediatric patients after renal transplantation.
Behnke B; Altrogge H; Delling G; Kruse HP; Müller-Wiefel DE
Clin Nephrol; 1996 Jul; 46(1):24-9. PubMed ID: 8832146
[TBL] [Abstract][Full Text] [Related]
4. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density in children with steroid-sensitive nephrotic syndrome.
Mishra OP; Meena SK; Singh SK; Prasad R; Mishra RN
Indian J Pediatr; 2009 Dec; 76(12):1237-9. PubMed ID: 19936659
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density and its influencing factors in children with idiopathic nephrotic syndrome: a prospective observational study.
Sharawat IK; Dawman L; Kumkhaniya MV; Devpura K; Mehta A
Trop Doct; 2019 Oct; 49(4):292-298. PubMed ID: 31408410
[TBL] [Abstract][Full Text] [Related]
7. Bone mass and biochemical markers of bone turnover in children and adolescents with chronic immune thrombocytopenia: relation to corticosteroid therapy and vitamin D receptor gene polymorphisms.
Tantawy AA; El Bostany EA; Matter RM; El Ghoroury EA; Ragab S; El Sherif NH
Platelets; 2013; 24(4):282-7. PubMed ID: 22671537
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome.
Kyrieleis HA; Levtchenko EN; Wetzels JF
Am J Kidney Dis; 2007 May; 49(5):592-7. PubMed ID: 17472840
[TBL] [Abstract][Full Text] [Related]
9. Effect of two prophylactic bolus vitamin D dosing regimens (1000 IU/day vs. 400 IU/day) on bone mineral content in new-onset and infrequently-relapsing nephrotic syndrome: a randomised clinical trial.
Muske S; Krishnamurthy S; Kamalanathan SK; Rajappa M; Harichandrakumar KT; Sivamurukan P
Paediatr Int Child Health; 2018 Feb; 38(1):23-33. PubMed ID: 28466679
[TBL] [Abstract][Full Text] [Related]
10. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease?
Gulati S; Godbole M; Singh U; Gulati K; Srivastava A
Am J Kidney Dis; 2003 Jun; 41(6):1163-9. PubMed ID: 12776267
[TBL] [Abstract][Full Text] [Related]
11. [Bone density in children and adolescents with rheumatic diseases. Preliminary results of selective measurement of trabecular and cortical bone using peripheral computerized tomography].
Lettgen B; Neudorf U; Hosse R; Peters S; Reiners C
Klin Padiatr; 1996; 208(3):114-7. PubMed ID: 8676598
[TBL] [Abstract][Full Text] [Related]
12. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie.
Arch Dis Child; 1987 Nov; 62(11):1102-6. PubMed ID: 3688915
[TBL] [Abstract][Full Text] [Related]
14. [Cyclophosphamide in idiopathic nephrotic syndrome: Outcome and outlook].
Berkane M; Adarmouch L; Amine M; Bourrahouat A; Ait Sab I; Sbihi M
Nephrol Ther; 2018 Apr; 14(2):85-90. PubMed ID: 29631702
[TBL] [Abstract][Full Text] [Related]
15. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
[TBL] [Abstract][Full Text] [Related]
16. Effects of steroid treatment on bone mineral metabolism in children with glucocorticoid-sensitive nephrotic syndrome.
Koşan C; Ayar G; Orbak Z
West Indian Med J; 2012 Sep; 61(6):627-30. PubMed ID: 23441359
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral content in nephrotic children on long-term, alternate-day prednisone therapy.
Polito C; La Manna A; Todisco N; Cimmaruta E; Sessa G; Pirozzi M
Clin Pediatr (Phila); 1995 May; 34(5):234-6. PubMed ID: 7628164
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook.
Vester U; Kranz B; Zimmermann S; Hoyer PF
Pediatr Nephrol; 2003 Jul; 18(7):661-4. PubMed ID: 12750975
[TBL] [Abstract][Full Text] [Related]
19. The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome.
Banerjee S; Basu S; Sen A; Sengupta J
Pediatr Nephrol; 2017 Nov; 32(11):2063-2070. PubMed ID: 28725977
[TBL] [Abstract][Full Text] [Related]
20. The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1.
Vester U; Kranz B; Zimmermann S; Büscher R; Hoyer PF
Pediatr Nephrol; 2005 Apr; 20(4):478-81. PubMed ID: 15717164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
